Company intelligence / Profile preview

Woods Medical Care

Busan, South Korea

Ownership: Private
Development stage: Other

Overview

Woods Medical Care, through its joint venture with Rafarma Pharmaceuticals, will produce and promote radiopharmaceuticals (notably Yttrium-90) for nuclear medicine in cancer treatment in East Asia, initially focusing on prostate and liver cancers; the production facility is in Busan Technology Park, South Korea

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Partnerships

Rafarma Pharmaceuticals

Beyond the preview

Go deeper on Woods Medical Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Woods Medical Care.

Explore the full profile